AU2019359878A1 - Data based cancer research and treatment systems and methods - Google Patents
Data based cancer research and treatment systems and methods Download PDFInfo
- Publication number
- AU2019359878A1 AU2019359878A1 AU2019359878A AU2019359878A AU2019359878A1 AU 2019359878 A1 AU2019359878 A1 AU 2019359878A1 AU 2019359878 A AU2019359878 A AU 2019359878A AU 2019359878 A AU2019359878 A AU 2019359878A AU 2019359878 A1 AU2019359878 A1 AU 2019359878A1
- Authority
- AU
- Australia
- Prior art keywords
- data
- sequencing
- database
- cancer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 253
- 238000011282 treatment Methods 0.000 title claims abstract description 251
- 238000011160 research Methods 0.000 title description 42
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 414
- 201000011510 cancer Diseases 0.000 claims abstract description 218
- 238000012163 sequencing technique Methods 0.000 claims abstract description 140
- 238000007493 shaping process Methods 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 112
- 230000008569 process Effects 0.000 claims description 86
- 230000000694 effects Effects 0.000 claims description 81
- 230000014509 gene expression Effects 0.000 claims description 57
- 210000004027 cell Anatomy 0.000 claims description 56
- 238000002560 therapeutic procedure Methods 0.000 claims description 56
- 210000001519 tissue Anatomy 0.000 claims description 55
- 108020004414 DNA Proteins 0.000 claims description 43
- 230000004927 fusion Effects 0.000 claims description 36
- 230000035772 mutation Effects 0.000 claims description 34
- 238000009169 immunotherapy Methods 0.000 claims description 29
- 238000003559 RNA-seq method Methods 0.000 claims description 27
- 210000004602 germ cell Anatomy 0.000 claims description 27
- 210000002220 organoid Anatomy 0.000 claims description 25
- 230000004044 response Effects 0.000 claims description 22
- 238000001712 DNA sequencing Methods 0.000 claims description 14
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 11
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 11
- 210000002865 immune cell Anatomy 0.000 claims description 11
- 230000001461 cytolytic effect Effects 0.000 claims description 8
- 230000002018 overexpression Effects 0.000 claims description 8
- 239000012661 PARP inhibitor Substances 0.000 claims description 7
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 230000037442 genomic alteration Effects 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 238000002659 cell therapy Methods 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 238000011369 optimal treatment Methods 0.000 claims description 4
- 101150049668 xt gene Proteins 0.000 claims description 4
- 108700020463 BRCA1 Proteins 0.000 claims description 3
- 102000036365 BRCA1 Human genes 0.000 claims description 3
- 101150072950 BRCA1 gene Proteins 0.000 claims description 3
- 102000052609 BRCA2 Human genes 0.000 claims description 3
- 108700020462 BRCA2 Proteins 0.000 claims description 3
- 101150008921 Brca2 gene Proteins 0.000 claims description 3
- 102100039788 GTPase NRas Human genes 0.000 claims description 3
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 3
- 102000043136 MAP kinase family Human genes 0.000 claims description 3
- 108091054455 MAP kinase family Proteins 0.000 claims description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 3
- 238000009175 antibody therapy Methods 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 3
- 108700042657 p16 Genes Proteins 0.000 claims description 3
- 108700001666 APC Genes Proteins 0.000 claims description 2
- 101150041972 CDKN2A gene Proteins 0.000 claims description 2
- 101150069156 Cdkn2b gene Proteins 0.000 claims description 2
- 101150029707 ERBB2 gene Proteins 0.000 claims description 2
- 101150039808 Egfr gene Proteins 0.000 claims description 2
- 101150105104 Kras gene Proteins 0.000 claims description 2
- 101150073900 PTEN gene Proteins 0.000 claims description 2
- 101150063858 Pik3ca gene Proteins 0.000 claims description 2
- 101150080074 TP53 gene Proteins 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 108700021358 erbB-1 Genes Proteins 0.000 claims description 2
- 101150046722 idh1 gene Proteins 0.000 claims description 2
- 108700025694 p53 Genes Proteins 0.000 claims description 2
- 238000012800 visualization Methods 0.000 claims description 2
- 101100002343 Arabidopsis thaliana ARID1 gene Proteins 0.000 claims 1
- 239000000047 product Substances 0.000 description 56
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 52
- 238000003556 assay Methods 0.000 description 48
- 238000004458 analytical method Methods 0.000 description 43
- 239000000523 sample Substances 0.000 description 38
- 230000001225 therapeutic effect Effects 0.000 description 32
- 208000032818 Microsatellite Instability Diseases 0.000 description 31
- 238000012360 testing method Methods 0.000 description 31
- 230000004075 alteration Effects 0.000 description 27
- 230000008707 rearrangement Effects 0.000 description 26
- 230000000392 somatic effect Effects 0.000 description 26
- 230000002068 genetic effect Effects 0.000 description 24
- 238000013439 planning Methods 0.000 description 23
- 239000000090 biomarker Substances 0.000 description 21
- 238000003745 diagnosis Methods 0.000 description 21
- 108091092878 Microsatellite Proteins 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 108700028369 Alleles Proteins 0.000 description 18
- 238000012015 optical character recognition Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- 238000001514 detection method Methods 0.000 description 14
- 230000000869 mutational effect Effects 0.000 description 13
- 238000004422 calculation algorithm Methods 0.000 description 12
- 238000007481 next generation sequencing Methods 0.000 description 12
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 230000008093 supporting effect Effects 0.000 description 10
- 108010074708 B7-H1 Antigen Proteins 0.000 description 9
- 102000008096 B7-H1 Antigen Human genes 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 230000009850 completed effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- 230000026676 system process Effects 0.000 description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 102100030708 GTPase KRas Human genes 0.000 description 4
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 4
- 101710104976 Interferon gamma-related Proteins 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 4
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229960003130 interferon gamma Drugs 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 230000033607 mismatch repair Effects 0.000 description 4
- 230000002250 progressing effect Effects 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 230000009452 underexpressoin Effects 0.000 description 4
- 101150106899 28 gene Proteins 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 102000001398 Granzyme Human genes 0.000 description 3
- 108060005986 Granzyme Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102100028467 Perforin-1 Human genes 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000013499 data model Methods 0.000 description 3
- 238000013079 data visualisation Methods 0.000 description 3
- 238000013503 de-identification Methods 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 208000002409 gliosarcoma Diseases 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000000771 oncological effect Effects 0.000 description 3
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000007637 random forest analysis Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000037439 somatic mutation Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 101150084750 1 gene Proteins 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 description 2
- 102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 230000004536 DNA copy number loss Effects 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 230000010558 Gene Alterations Effects 0.000 description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 2
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 description 2
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000008711 chromosomal rearrangement Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000007635 classification algorithm Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000012913 prioritisation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 101150042997 21 gene Proteins 0.000 description 1
- 102100034580 AT-rich interactive domain-containing protein 1A Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
- 102100030386 Granzyme A Human genes 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101100435489 Homo sapiens ARID1A gene Proteins 0.000 description 1
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 1
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 description 1
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101000979599 Homo sapiens Protein NKG7 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000826399 Homo sapiens Sulfotransferase 1A1 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- -1 ID01 Proteins 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 230000037364 MAPK/ERK pathway Effects 0.000 description 1
- 102100026371 MHC class II transactivator Human genes 0.000 description 1
- 108700002010 MHC class II transactivator Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 102100023370 Protein NKG7 Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102100029197 SLAM family member 6 Human genes 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102100023986 Sulfotransferase 1A1 Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011220 combination immunotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000021991 hereditary neoplastic syndrome Diseases 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 230000009397 lymphovascular invasion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 206010034260 pelvic mass Diseases 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000024977 response to activity Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000014653 solitary fibrous tumor Diseases 0.000 description 1
- 238000012358 sourcing Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 108010064892 trkC Receptor Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000012049 whole transcriptome sequencing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746997P | 2018-10-17 | 2018-10-17 | |
| US62/746,997 | 2018-10-17 | ||
| US62/902,950 | 2019-09-19 | ||
| PCT/US2019/056713 WO2020081795A1 (fr) | 2018-10-17 | 2019-10-17 | Systèmes et procédés de recherche et de traitement du cancer basés sur des données |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019359878A1 true AU2019359878A1 (en) | 2021-05-27 |
Family
ID=70284254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019359878A Pending AU2019359878A1 (en) | 2018-10-17 | 2019-10-17 | Data based cancer research and treatment systems and methods |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2019359878A1 (fr) |
| CA (1) | CA3116712A1 (fr) |
| WO (1) | WO2020081795A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111816315B (zh) * | 2020-05-28 | 2023-10-13 | 上海市生物医药技术研究院 | 胰腺导管癌状态评估模型构建方法及应用 |
| WO2021247905A1 (fr) * | 2020-06-04 | 2021-12-09 | Xcures, Inc. | Procédés et systèmes pour oncologie de précision utilisant un modèle bayésien à plusieurs niveaux |
| WO2023150285A1 (fr) * | 2022-02-04 | 2023-08-10 | Elixirgen Therapeutics, Inc. | Systèmes et méthodes de protocole de thérapie cellulaire |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100029498A1 (en) * | 2008-02-04 | 2010-02-04 | Andreas Gnirke | Selection of nucleic acids by solution hybridization to oligonucleotide baits |
| US20150324527A1 (en) * | 2013-03-15 | 2015-11-12 | Northrop Grumman Systems Corporation | Learning health systems and methods |
| US20140365242A1 (en) * | 2013-06-07 | 2014-12-11 | Siemens Medical Solutions Usa, Inc. | Integration of Multiple Input Data Streams to Create Structured Data |
| US10642854B2 (en) | 2016-10-07 | 2020-05-05 | Sudeep Pattnaik | Clinical data aggregation architecture and platform |
-
2019
- 2019-10-17 WO PCT/US2019/056713 patent/WO2020081795A1/fr unknown
- 2019-10-17 AU AU2019359878A patent/AU2019359878A1/en active Pending
- 2019-10-17 CA CA3116712A patent/CA3116712A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020081795A1 (fr) | 2020-04-23 |
| CA3116712A1 (fr) | 2020-04-23 |
| WO2020081795A8 (fr) | 2020-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200258601A1 (en) | Targeted-panel tumor mutational burden calculation systems and methods | |
| Beaubier et al. | Integrated genomic profiling expands clinical options for patients with cancer | |
| US11705226B2 (en) | Data based cancer research and treatment systems and methods | |
| US20210118559A1 (en) | Artificial intelligence assisted precision medicine enhancements to standardized laboratory diagnostic testing | |
| Nicolosi et al. | Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines | |
| US11640859B2 (en) | Data based cancer research and treatment systems and methods | |
| Mathias et al. | A continuum of admixture in the Western Hemisphere revealed by the African Diaspora genome | |
| US20200381087A1 (en) | Systems and methods of clinical trial evaluation | |
| Gymrek et al. | Identifying personal genomes by surname inference | |
| Graff et al. | Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts | |
| De Leeuw et al. | Diagnostic interpretation of array data using public databases and internet sources | |
| CA3137168A1 (fr) | Procede et systeme d'intelligence artificielle collaborative | |
| JP6231654B2 (ja) | 疾患関連ヒトゲノム変異体の解析とレポート作成のシステムと方法 | |
| EP3631657B1 (fr) | Système et procédé de détection de fusion de gènes | |
| Rockowitz et al. | Children’s rare disease cohorts: an integrative research and clinical genomics initiative | |
| WO2020081795A1 (fr) | Systèmes et procédés de recherche et de traitement du cancer basés sur des données | |
| Mirshahi et al. | A genome-first approach to characterize DICER1 pathogenic variant prevalence, penetrance, and phenotype | |
| Roy et al. | SeqReporter: automating next-generation sequencing result interpretation and reporting workflow in a clinical laboratory | |
| Carter et al. | Electronic health records and genomics: perspectives from the association for molecular pathology electronic health record (EHR) interoperability for clinical genomics data working group | |
| Yohe et al. | Standards for clinical grade genomic databases | |
| US20230245788A1 (en) | Data based cancer research and treatment systems and methods | |
| Cirulli et al. | A power-based sliding window approach to evaluate the clinical impact of rare genetic variants in the nucleotide sequence or the spatial position of the folded protein | |
| Furness | Bridging the gap: the need for genomic and clinical-omics data integration and standardization in overcoming the bottleneck of variant interpretation | |
| Wood et al. | Burden of tumor mutations, neoepitopes, and other variants are dubious predictors of cancer immunotherapy response and overall survival | |
| US20190267114A1 (en) | Device for presenting sequencing data |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 62/746,997 17 OCT 2018 US AND 62/902,950 19 SEP 2019 US |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ COLLEY, SHANE; SIMPSON, ISAIAH; REUTER, BRIAN; TELL, ROBERT; LEFKOFSKI, HAILEY; LANE, HUNTER; WHITE, KEVIN; BEAUBIER, NIKE; BUSH, STEPHEN; KHAN, ALY; LAU, DENISE; SHAH, KAANAN AND LEFKOFSKY, ERIC |
|
| HB | Alteration of name in register |
Owner name: TEMPUS AI, INC. Free format text: FORMER NAME(S): TEMPUS LABS, INC. |